Michael Bookman

CIK: 0001840339

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IMRX

Immuneering Corp

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

IMRX
Immuneering Corp
Feb 3, 2026
Award(A)
Stock Option
Direct
176K shares-
IMRX
Immuneering Corp
Oct 1, 2025
Purchase(P)
Direct
1K shares at avg. $6.83$7K
IMRX
Immuneering Corp
Feb 5, 2025
Award(A)
Stock Option
Direct
110K shares-

		Type	Shares	Price		Ownership
Feb 3, 2026	IMRX Immuneering Corp	Award(A) Stock Option	176,000	-	-	Direct
Oct 1, 2025	IMRX Immuneering Corp	Purchase(P)	1,020	$6.83	$6,966	Direct
Feb 5, 2025	IMRX Immuneering Corp	Award(A) Stock Option	110,000	-	-	Direct

1-3 of 3 transactions

About Bookman Michael

Bookman Michael (SEC CIK 0001840339) files insider reports with the SEC as CHIEF LEGAL OFFICER, SECRETARY of Immuneering Corp (IMRX).

Signal8 holds 3 ownership filings by Bookman Michael, all Form 4s, filed between Feb 7, 2025 and Feb 5, 2026. Those filings report 3 transactions, from Feb 5, 2025 to Feb 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bookman Michael's filings is in CAMBRIDGE, MA.

Recent filings by Bookman Michael

Feb 3, 2026: Grant or award of IMRX derivative securities (Form 4, code A).
Oct 1, 2025: Open-market purchase of IMRX shares (Form 4, code P).
Feb 5, 2025: Grant or award of IMRX derivative securities (Form 4, code A).

Other insiders filing for Immuneering Corp (IMRX)

Gengos Andrew, Chief Financial Officer
Zeskind Benjamin J., PRESIDENT AND CEO
Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER
Schall Thomas J., Director
HAUSMAN DIANA, Director
CARPENTER ROBERT J, Director

How to read Form 4 transaction codes